These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12583551)

  • 1. Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model.
    Jasovich A; Soutric J; Morera G; Mastruzzo M; Vesco E; Izaguirre M; Mobilia L; Prieto S; Franco D; Curcio D; Absi R; Larrateguy L; Bustos JL; Oliva ME; Arenoso H; Bantar C
    J Chemother; 2002 Dec; 14(6):591-6. PubMed ID: 12583551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2001 Aug; 13(4):402-6. PubMed ID: 11589483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
    Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
    J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.
    el Moussaoui R; de Borgie CA; van den Broek P; Hustinx WN; Bresser P; van den Berk GE; Poley JW; van den Berg B; Krouwels FH; Bonten MJ; Weenink C; Bossuyt PM; Speelman P; Opmeer BC; Prins JM
    BMJ; 2006 Jun; 332(7554):1355. PubMed ID: 16763247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of childhood complicated community-acquired pneumonia with amoxicillin/sulbactam.
    Lovera D; Arbo A
    J Chemother; 2005 Jun; 17(3):283-8. PubMed ID: 16038522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
    Kohno S; Tateda K; Mikamo H; Kadota J; Niki Y; Itamura R
    J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
    Petitpretz P; Arvis P; Marel M; Moita J; Urueta J;
    Chest; 2001 Jan; 119(1):185-95. PubMed ID: 11157603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults].
    Trémolières F; Mayaud C; Mouton Y; Weber P; Dellatolas F; Caulin E
    Pathol Biol (Paris); 2005; 53(8-9):503-10. PubMed ID: 16181747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate-severe community-acquired pneumonia.
    El Moussaoui R; Opmeer BC; de Borgie CA; Nieuwkerk P; Bossuyt PM; Speelman P; Prins JM
    Chest; 2006 Oct; 130(4):1165-72. PubMed ID: 17035452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amoxicillin-sulbactam versus amoxicillin-clavulanic acid for the treatment of non-recurrent-acute otitis media in Argentinean children.
    Casellas JM; Israele V; Marín M; Ishida MT; Heguilen R; Soutric J; Arenoso H; Sibbald A; Stamboulian D
    Int J Pediatr Otorhinolaryngol; 2005 Sep; 69(9):1225-33. PubMed ID: 16061111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan.
    Kohno S; Yanagihara K; Yamamoto Y; Tokimatsu I; Hiramatsu K; Higa F; Tateyama M; Fujita J; Kadota J
    J Infect Chemother; 2013 Dec; 19(6):1035-41. PubMed ID: 23695232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
    Shorr AF; Khashab MM; Xiang JX; Tennenberg AM; Kahn JB
    Respir Med; 2006 Dec; 100(12):2129-36. PubMed ID: 16730170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
    Paris R; Confalonieri M; Dal Negro R; Ligia GP; Mos L; Todisco T; Rastelli V; Perna G; Cepparulo M
    J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
    Prabhudesai PP; Jain S; Keshvani A; Kulkarni KP
    J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.